Cronos Group Inc. (CRON) stock
CRONNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 15/307% below fair value
$3.38−0.03 (-0.88%)
Close on Nov 13, 2026Market cap $1.25BP/E 19.9Yield –
Cronos r&d expenses
Research and development expenses are spending on new products and technology.
Cronos's R&D Expenses for the twelve months ending Sep 30, 2026 was $5.35M, up 30.5% year over year. For fiscal 2025 it was $4.45M, up 5.2% from the year before. The highest annual figure on record is $21.84M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.45M | +5.2% |
| FY2024 | Dec 31, 2024 | $4.23M | -27.6% |
| FY2023 | Dec 31, 2023 | $5.84M | -55.5% |
| FY2022 | Dec 31, 2022 | $13.13M | -39.9% |
| FY2021 | Dec 31, 2021 | $21.84M | +7.2% |
| FY2020 | Dec 31, 2020 | $20.37M | +67.6% |
| FY2019 | Dec 31, 2019 | $12.16M | +570.1% |
| FY2018 | Dec 31, 2018 | $1.81M | – |
| FY2017 | Dec 31, 2017 | $0 | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.34M | -0.7% |
| Q2 FY2026 | Jun 30, 2026 | $1.22M | +30.8% |
| Q1 FY2026 | Mar 31, 2026 | $1.41M | +78.2% |
| Q4 FY2025 | Dec 31, 2025 | $1.38M | +34.4% |
| Q3 FY2025 | Sep 30, 2025 | $1.35M | +8.3% |
| Q2 FY2025 | Jun 30, 2025 | $929.00K | -3.4% |
| Q1 FY2025 | Mar 31, 2025 | $793.00K | -20.5% |
| Q4 FY2024 | Dec 31, 2024 | $1.03M | -29.2% |
| Q3 FY2024 | Sep 30, 2024 | $1.24M | -0.3% |
| Q2 FY2024 | Jun 30, 2024 | $962.00K | -13.1% |
| Q1 FY2024 | Mar 31, 2024 | $997.00K | -51.1% |
| Q4 FY2023 | Dec 31, 2023 | $1.45M | -41.4% |
| Q3 FY2023 | Sep 30, 2023 | $1.25M | -51.0% |
| Q2 FY2023 | Jun 30, 2023 | $1.11M | -73.6% |
| Q1 FY2023 | Mar 31, 2023 | $2.04M | -49.5% |
| Q4 FY2022 | Dec 31, 2022 | $2.48M | -51.2% |
| Q3 FY2022 | Sep 30, 2022 | $2.54M | -60.7% |
| Q2 FY2022 | Jun 30, 2022 | $4.19M | -19.3% |
| Q1 FY2022 | Mar 31, 2022 | $4.04M | -20.8% |
| Q4 FY2021 | Dec 31, 2021 | $5.07M | -31.6% |
| Q3 FY2021 | Sep 30, 2021 | $6.47M | +36.7% |
| Q2 FY2021 | Jun 30, 2021 | $5.20M | +43.2% |
| Q1 FY2021 | Mar 31, 2021 | $5.10M | +11.2% |
| Q4 FY2020 | Dec 31, 2020 | $7.41M | +21.9% |
| Q3 FY2020 | Sep 30, 2020 | $4.73M | +81.7% |
| Q2 FY2020 | Jun 30, 2020 | $3.63M | +57.9% |
| Q1 FY2020 | Mar 31, 2020 | $4.59M | +292.0% |
| Q4 FY2019 | Dec 31, 2019 | $6.08M | – |
| Q3 FY2019 | Sep 30, 2019 | $2.61M | – |
| Q2 FY2019 | Jun 30, 2019 | $2.30M | – |
| Q1 FY2019 | Mar 31, 2019 | $1.17M | – |
See a number that looks wrong?